# US 2016/0256394 A1 · Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256394 A1
- Document ID: US20160256394A1
- Status: Published application
- Kind: A1
- Application number: 15/029,215
- Filed: 2014-10-13
- Published: 2016-09-08
- Earliest claimed: 2013-10-17
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Heike NEUMANN; Klaus BENKE; Michael FORMELL; Gabriele WINTER
- Web page: https://patentgrep.com/patent/US20160256394A1

## CPC

- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to solid pharmaceutical dosage forms for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for the preparation thereof, use thereof as medicaments, and also use thereof for prophylaxis, secondary prophylaxis or treatment of disorders, particularly cardiovascular disorders, heart failure, anaemia, chronic renal disorders and renal insufficiency.

## Claims

### Claim 1

A solid pharmaceutical dosage form for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), characterized in that
(a) the concentration of auxiliaries having divalent and/or trivalent cations is ≦0.1% based on a total mass of the formulation,
(b) the concentration of lactose is ≦10% based on the total mass of the formulation,
(c) the concentration of active ingredient (I) is ≦10% based on the total mass of the formulation, and
(d) if the dosage form has a film coating, the film coating does not comprise polyethylene glycol.

### Claim 2 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that
(e) the active ingredient (I) is released rapidly.

### Claim 3 (depends on 2)

The solid pharmaceutical dosage form of claim 2, characterized in that at least 85% of active ingredient (I) are released per test specimen into the release medium after 30 minutes, from 6 test specimens relating to the pharmaceutical dosage form, according to the release method of the European Pharmacopoeia using apparatus 2 (paddle).

### Claim 4 (depends on 3)

The solid pharmaceutical dosage form of claim 3, characterized in that the release medium consists of 900 ml of 0.1N hydrochloric acid.

### Claim 5 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that the dosage form is a tablet.

### Claim 6 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that the concentration of the active ingredient (I) is 10 to 40% based on the total mass of the formulation.

### Claim 7 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that no auxiliaries having divalent and/or trivalent cations are present.

### Claim 8 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that no lactose is present.

### Claim 9 (depends on 1)

The solid pharmaceutical dosage form of claim 1, characterized in that at least one filler and at least one lubricant are present as auxiliaries.

### Claim 10 (depends on 9)

The solid pharmaceutical dosage form of claim 9, characterized in that the filler is microcrystalline cellulose or mannitol or a mixture of microcrystalline cellulose and mannitol.

### Claim 11 (depends on 9)

The solid pharmaceutical dosage form of claim 9, characterized in that the lubricant is sodium stearyl fumarate or glyceryl distearate.

### Claim 12 (depends on 5)

The solid pharmaceutical dosage form of claim 5, characterized in that the tablet has a film coating.

### Claim 13

A method of making a solid pharmaceutical dosage form for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), a concentration of auxiliaries having divalent and/or trivalent cations ≦0.1% based on the total mass of the formulation, a concentration of lactose ≦10% based on the total mass of the formulation and a concentration of active ingredient (I) ≧10% based on the total mass of the formulation, characterized in that
(a) a granulate comprising the active ingredient (I) is initially prepared and
(b) the granulate, optionally with addition of pharmaceutically acceptable auxiliaries, is then converted into the pharmaceutical dosage form.

### Claim 14 (depends on 13)

The method of claim 13, characterized in that the granulate is prepared by wet granulation.

### Claim 15 (depends on 4)

The method of claim 4, characterized in that fluidized bed granulation is used as the wet granulation method.
